← All indications
Diabetes Mellitus, Type 1
A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.
Subtype terms (1)
More specific conditions that are subtypes of Diabetes Mellitus, Type 1 in the MeSH hierarchy.
- Wolfram Syndrome
6 drugs approved
Drugs by status
Approved for this indication (9)
Phase 4 trials (57)
- metformin
- ezetimibe
- allopurinol
- 23-valent pneumococcal polysaccharide vaccine
- vitamin d3
- vitamin e
- oak extract
- insulin glulisine
- berberine
- bifidobacterium animalis
- candesartan
- exenatide
- diazoxide
- empagliflozin
- ethanol
- liraglutide
- glyburide
- insulin human
- insulin degludec
- inulin
- hyaluronidase (human recombinant)
- lixisenatide
- hemoglobin
- vitamin c
- evolocumab
- atorvastatin
- febuxostat
- saxagliptin
- sitagliptin
- semaglutide
- +27 more
Phase 3 trials (50)
- olbetam
- allogeneic pancreatic islet cells
- captopril
- otelixizumab
- cinnamon
- alpha-lipoic acid
- daclizumab
- ladarixin
- diapep277
- ebselen
- etanercept
- finerenone
- tacrolimus
- iloperidone
- baricitinib
- ipragliflozin
- ly3209590
- ruboxistaurin mesylate
- miglitol
- myoinositol
- ranolazine
- reparixin
- diamyd
- salsalate
- cyclosporine
- tropicamide
- ttp399
- Anti-thymocyte Globulin (Rabbit)
- ustekinumab
- verapamil
- +20 more
Phase 2 trials (142)
- simvastatin
- tzp-102
- heparin
- iron
- methylprednisolone
- denosumab
- acetazolamide
- secukinumab
- alagebrium
- allostim
- alum-gad
- plerixafor
- amitriptyline
- acetylcysteine
- bacille calmette-guerin
- sorafenib
- alprazolam
- ambrisentan
- c-peptide
- canakinumab
- bardoxolone
- cfz533
- chlorthalidone
- golimumab
- deferoxamine
- prednisone
- ibuprofen
- dextran
- alpha-1 antitrypsin
- dulaglutide
- +112 more
Phase 1 trials (90)
- melatonin
- sodium citrate
- maltodextrin
- 18f-fp-dtbz
- fluticasone
- spirulina
- pitolisant
- azd1656
- urea
- c19-a3 gnp
- pancrelipase
- sodium dichloroacetate
- dehydroepiandrosterone
- diabetes-suppressive dendritic cell
- eflornithine
- somatropin
- leptin
- hm12470
- ibc-vs01
- icosapent ethyl
- terbutaline
- insulin 287
- insulin 338
- bmx-010
- fluoxetine
- mk-2640
- ms-553
- multipept1de
- nbi-6024
- nn1952
- +60 more
Other trials (90)
- phenylephrine
- nitroglycerin
- 68ga-exendin
- fallypride
- lubiprostone
- oxytocin
- beta carotene
- beta-hydroxybutyrate
- epoetin
- carbon dioxide
- l-carnosine
- colesevelam
- chromium niacinate
- lipopolysaccharide
- dark chocolate
- fludrocortisone
- folic acid
- gastric inhibitory polypeptide
- gip (1-42)
- l-glutamine
- hemin
- amlodipine
- adenosine
- mecasermin
- nevulose
- acetylcholine chloride
- whey protein
- levocarnitine
- somatostatin
- gip
- +60 more
Organizations
Organization Involved with Phase 4 Indications (97)
- University of London
- University of Toulouse
- Yeshiva University
- Newcastle University
- University of Southern California
- University of New South Wales
- University of Bern
- Cairo University
- Tulane University
- Command Hospital, India
- Rainier Clinical Research Center
- Profil GmbH
- Canadian Institutes of Health Research (CIHR)
- University of Exeter
- University of Toronto
- Sydvestjysk Hospital
- The Spectrum Health Group
- Nanjing Medical University
- Norwegian University of Science and Technology
- University of Pittsburgh
- The University of Texas, Dallas
- University of Campania Luigi Vanvitelli
- University of Oxford
- University Diabetes & Endocrine Consultants
- Atlanta Diabetes Associates
- Aristotle University of Thessaloniki
- Sansum Diabetes Research Institute
- National Clinical Research Center for Metabolic Diseases, China
- Sanofi
- National Institutes of Health (NIH)
- +67 more
Organization Involved with Phase 3 Indications (112)
- Vita-Salute University of Milano. Italy
- Dompe Pharmaceuticals
- Itamar-Medical, Israel
- Reproductive Endocrinology Associates of Charlotte
- University of Oslo
- MacroGenics
- University of Chicago
- University of Illinois at Chicago
- British Heart Foundation
- People's Liberation Army of China
- Gan and Lee Pharmaceuticals, USA
- Astellas
- University of Pennsylvania
- Abbott
- Wyeth
- Zealand Pharma
- DexCom, Inc.
- University of Minnesota
- Merck Serono
- University of Grenoble
- University of California, San Francisco
- Northwestern University
- University of Melbourne
- General Committee of Teaching Hospitals and Institutes, Egypt
- Xeris Pharmaceuticals
- Roche
- University of Western Australia
- Hospital of Southwest Denmark
- Assistance Publique - Hôpitaux de Paris
- Melbourne Health
- +82 more
Organization Involved with Phase 2 Indications (142)
- Washington University in St. Louis
- Universidad del Desarrollo
- ViaCyte
- NextCell Pharma
- Cardiff University
- Health Resources and Services Administration (HRSA)
- Oshadi Drug Administration
- University of Antwerp
- Diabetes Research Institute Foundation
- TFS Trial Form Support
- Cebix Incorporated
- Sangamo BioSciences
- The Cleveland Clinic
- CHRISTUS Health
- Diabetes Canada
- Statistika Consultoria Ltda
- Diasome Pharmaceuticals
- University of Virginia
- Osaka University
- Worldwide Clinical Trials
- The Foundation Institute San Raffaele G. Giglio of Cefalù
- Stem Cells Arabia
- Yale University
- Technical University of Dresden
- Tranzyme, Inc.
- Erasmus University Rotterdam
- Sir Jules Thorn Charitable Trust
- Diabetes and Glandular Disease Research Associates Inc.
- Alberta Innovates Health Solutions
- CPEX Pharmaceuticals
- +112 more
Organization Involved with Phase 1 Indications (56)
- Vanderbilt University
- University of Calgary
- Regenerative Medicine Minnesota
- Healthcare Discoveries Inc.
- Takeda
- DiObex
- Augusta University
- ProtoKinetix Inc.
- University of Barcelona
- CAR-T (Shanghai) Biotechnology Co.,Ltd.
- European Union
- Vanilloid Genetics Inc.
- Children's Hospital Research Institute of Manitoba
- Bharti Hospital
- University of Maryland
- Diacon Hospital, Bangalore
- Locemia Solutions ULC
- Neurocrine Biosciences
- Institut Cochin
- Bangalore Diabetes Hospital
- Omni Bio Pharmaceutical, Inc.
- Benaroya Research Institute
- Transition Therapeutics
- Stony Brook University
- Perosphere, Inc.
- The Health Sciences Centre Medical Staff Council
- University of Lorraine
- Motus Therapeutics, Inc.
- Hanmi Pharmaceutical
- BioMimetix Pharmaceutical, Inc.
- +26 more
Organization Involved with Other Experimental Indications (52)
- Case Western Reserve University
- University of Hull
- University of Reims
- Chattanooga-Hamilton County Hospital Authority
- Fondazione G.B. Bietti, IRCCS
- Free University of Amsterdam
- Tanta University
- ACell Inc.
- Louisiana State University
- Dutch Diabetes Research Foundation
- Celltrans
- The Paul Manning Foundation
- University of Strasbourg
- CHU Besançon
- Ghent University
- Rio de Janeiro State University
- University of Amsterdam
- Central Hospital, Dijon, France
- Southern Medical University
- University of Naples Frederico II
- Postgraduate Institute of Medical Education and Research
- Central Hospital, Metz Thionville, France
- Diabetes Care Center
- ImmusanT, Inc.
- Natreon, Inc.
- University of Burgundy
- Daiichi Sankyo
- University Hospital Hradec Kralove
- Université catholique de Louvain
- Government of Belgium
- +22 more